New medicine to help highly sensitised children receive kidney transplants
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The child must be between 1 and 17 years old and waiting for a kidney transplant.
- The child must have a very high level of antibodies (80% or more) that make it hard to find a matching kidney.
- Previous attempts to lower these antibodies (like plasmapheresis or IVIg) have not worked, or doctors think they would be too difficult.
- A test shows the donor kidney would likely be rejected (positive crossmatch) unless treated.
- The child must be healthy enough for transplant surgery and must not have had certain infections or treatments in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called imlifidase, which may help clear the antibodies that make it hard for highly sensitized patients to receive a kidney from a deceased donor. If you qualify, this treatment could increase your chances of getting a transplant.
This early-phase trial tests a new therapy that uses your own immune cells to reduce your body's attack on a new kidney. It aims to help people who are highly sensitized (hard to match) get a transplant successfully.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This trial tests an experimental drug called om336 to lower antibodies that make it hard to receive a kidney transplant. It aims to help people who have been waiting a long time for a kidney due to high antibody levels.
This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
Hear when a new Kidney Transplantation in Highly Sensitized Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.